cigb-300

CIGB-300 is a synthetic, cell-permeable cyclic peptide designed to inhibit casein kinase 2 (CK2), a serine/threonine protein kinase frequently overexpressed in various cancers. The drug acts by binding to the phosphoacceptor sites of CK2 substrates, particularly targeting the oncoprotein nucleophosmin (NPM1/B23), thereby blocking its activation and inducing apoptosis in tumor cells. This dual mechanism involves both substrate binding and direct inhibition of CK2 enzymatic activity, resulting in antineoplastic effects such as impaired proliferation, antiangiogenic activity, and potential synergy with other anticancer agents. Developed by the Cuban Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología), CIGB-300 has been investigated primarily for oncology indications including cervical cancer (squamous cell carcinoma and adenocarcinoma), acute myeloid leukemia, lung cancer, myelodysplastic syndromes, condyloma acuminata (genital warts), and COVID-19[1][2][3][4][5][6][7].

Other names

CHEBI:83696